Response to Comment on “Effect of Belimumab on Preventing De Novo Renal Lupus Flares” by Ioannis Parodis, Alvaro Gomez, Julius Lindblom, Brad H. Rovin

Get full text

The Evolution of Crescents in Lupus Nephritis by Ana Malvar, Valeria Alberton, Bruno Lococo, Serventi J. Martinez, Ignacio Chidid, Ricardo Heguilen, Brad H. Rovin

Get full text

Case Studies of Sustained Remission of Membranous Glomerulonephritis With Dupilumab Treatment by Mark H. Kaplan, Jessica M. Greco, Brad H. Rovin, Anthony M. Cannon, Abigail Pajulas, Jeffrey B. Travers, Ayman Hallab, Matthew J. Turner

Get full text

Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop by Marco Prunotto, Patrick H. Nachman, Barbara S. Gillespie, Laurence H. Beck, Aliza M. Thompson, Austin H. Hu, Elizabeth A. Stafford, Josh M. Tarnoff, Brad H. Rovin

Get full text

WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL by Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt

Get full text

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL by Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimír Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Richard Lafayette

Get full text

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy by Brad H. Rovin, Pierre M. Ronco, Jack F.M. Wetzels, Sharon G. Adler, Isabelle Ayoub, Philippe Zaoui, Seung Hyeok Han, Jaideep S. Dudani, Houston N. Gilbert, Uptal D. Patel, Paul T. Manser, Julia Jauch-Lembach, Nicola Faulhaber, Rainer Boxhammer, Stefan Härtle, Ben Sprangers

Get full text